The Investor
19 Nov 2026, 17:02
Abbott Starts VOYAGER Trial for Software-Guided Encantor TAVI System
Abbott (NYSE: ABT) initiated the VOYAGER CE clinical trial evaluating its investigational Encantor balloon-expandable transcatheter aortic valve implantation system for patients with symptomatic severe aortic stenosis.
The prospective, single-arm study will enroll up to 300 patients in Europe and Australia and is intended to support regulatory approval in those markets. Encantor uses software-guided deployment to tailor valve expansion to individual patient anatomy, with the goal of improving implantation precision and procedural consistency.
The platform is designed to complement Abbott’s existing Navitor self-expanding TAVI system, giving physicians a balloon-expandable alternative within the company’s structural heart portfolio. Abbott said early feasibility data supported advancement into the VOYAGER CE trial, while a U.S. pivotal study is planned in the coming months.
The trial represents an important development milestone for Abbott’s structural heart business, but Encantor remains investigational and is not yet approved for commercial use. Successful clinical and regulatory progress could broaden Abbott’s competitive position in the transcatheter heart-valve market over the longer term.
Abbott (NYSE: ABT) initiated the VOYAGER CE clinical trial evaluating its investigational Encantor balloon-expandable transcatheter aortic valve implantation system for patients with symptomatic severe aortic stenosis.
The prospective, single-arm study will enroll up to 300 patients in Europe and Australia and is intended to support regulatory approval in those markets. Encantor uses software-guided deployment to tailor valve expansion to individual patient anatomy, with the goal of improving implantation precision and procedural consistency.
The platform is designed to complement Abbott’s existing Navitor self-expanding TAVI system, giving physicians a balloon-expandable alternative within the company’s structural heart portfolio. Abbott said early feasibility data supported advancement into the VOYAGER CE trial, while a U.S. pivotal study is planned in the coming months.
The trial represents an important development milestone for Abbott’s structural heart business, but Encantor remains investigational and is not yet approved for commercial use. Successful clinical and regulatory progress could broaden Abbott’s competitive position in the transcatheter heart-valve market over the longer term.